Serious TEAEs and Serious Infections
Serious TEAEs and serious infections are also evaluated against the
filgotinib and GS-829845 exposures and no exposure-driven patterns were
present based on the safety data up to Week 52 (Supplementary Figure 1).
Overall, the exposure-safety relationships for either filgotinib and
GS-829845 demonstrate no trend toward increasing incidence of common
TEAEs, common laboratory abnormalities, serious TEAEs, or serious
infections with increasing exposure.